Literature DB >> 24041349

Benchmarks for interpretation of score differences on the SF-36 health survey for patients with diabetes.

Jakob B Bjorner1, Michael Lyng Wolden, Jens Gundgaard, Kate A Miller.   

Abstract

OBJECTIVE: To estimate clinical and social benchmarks for interpretation of score differences on the Short-Form 36 Health Survey, and apply these benchmarks to populations with diabetes mellitus (DM).
METHODS: Using survival and logistic regression models, we reanalyzed data from three US cohorts: the Medical Outcomes Study (N = 3,445; 541 patients with DM), the Medicare Health Outcomes Survey (N = 78,183; 16,388 patients with DM), and the QualityMetric 2009 Norming Study (N = 4,040; 580 patients with DM). Outcome variables were mortality, hospitalization, current inability to work, and loss of ability to work.
RESULTS: Benchmarks were robust across disease groups, but varied according to age and score level. A 1-point lower score on the Physical Function, General Health, and Physical Component Summary scales was associated with a 1.05 to 1.09 relative risk (RR) of mortality for the typical patient with DM, with stronger associations in the younger age groups. For several scales (Physical Function, Role Physical, Bodily Pain, General Health, Vitality, Social Function, and Role Emotional), the associations with mortality also depended on score level, with stronger associations in the lower score ranges (i.e., patients in worse health). A 1-point lower score on the Physical Function, Role Physical, Bodily Pain, General Health, Vitality, Social Function, and Physical Component Summary scales implied a 1.02 to 1.04 RR of hospitalization, a 1.07 to 1.12 RR of being unable to work, and a 1.04 to 1.07 RR of losing the ability to work.
CONCLUSIONS: A 1-point lower score on selected Short-Form 36 Health Survey scales is associated with an excess risk of up to 9% for mortality and 12% for inability to work.
Copyright © 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Entities:  

Keywords:  SF-36; benchmarks; diabetes; interpretation; patient-reported outcome

Mesh:

Year:  2013        PMID: 24041349     DOI: 10.1016/j.jval.2013.06.022

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  23 in total

1.  Reduction in physical function in women after venous thromboembolism.

Authors:  K A Hagan; L B Harrington; J Kim; O Zeleznik; E B Rimm; F Grodstein; C Kabrhel
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

2.  A dance intervention for cancer survivors and their partners (RHYTHM).

Authors:  Maria Pisu; Wendy Demark-Wahnefried; Kelly M Kenzik; Robert A Oster; Chee Paul Lin; Sharon Manne; Ronald Alvarez; Michelle Y Martin
Journal:  J Cancer Surviv       Date:  2017-01-09       Impact factor: 4.442

3.  Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Authors:  Eric D Foster; Nancy D Bridges; Irene D Feurer; Thomas L Eggerman; Lawrence G Hunsicker; Rodolfo Alejandro
Journal:  Diabetes Care       Date:  2018-03-21       Impact factor: 19.112

4.  Peer-Led Self-Management of General Medical Conditions for Patients With Serious Mental Illnesses: A Randomized Trial.

Authors:  Benjamin G Druss; Manasvini Singh; Silke A von Esenwein; Gretl E Glick; Stephanie Tapscott; Sherry Jenkins Tucker; Cathy A Lally; Evelina W Sterling
Journal:  Psychiatr Serv       Date:  2018-02-01       Impact factor: 3.084

5.  Association Between Chronic Conditions and Physical Function Among Veteran and Non-Veteran Women With Diabetes.

Authors:  Kristen E Gray; Jodie G Katon; Eileen Rillamas-Sun; Lori A Bastian; Karin M Nelson; Andrea Z LaCroix; Gayle E Reiber
Journal:  Gerontologist       Date:  2016-02

6.  Gastric bypass significantly improves quality of life in morbidly obese patients with type 2 diabetes.

Authors:  Philip Omotosho; Alessandro Mor; Prapimporn Chattranukulchai Shantavasinkul; Leonor Corsino; Alfonso Torquati
Journal:  Surg Endosc       Date:  2016-01-28       Impact factor: 4.584

Review 7.  Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.

Authors:  Bianca Hemmingsen; David P Sonne; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2017-05-10

8.  Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes.

Authors:  James F Markmann; Michael R Rickels; Thomas L Eggerman; Nancy D Bridges; David E Lafontant; Julie Qidwai; Eric Foster; William R Clarke; Malek Kamoun; Rodolfo Alejandro; Melena D Bellin; Kathryn Chaloner; Christine W Czarniecki; Julia S Goldstein; Bernhard J Hering; Lawrence G Hunsicker; Dixon B Kaufman; Olle Korsgren; Christian P Larsen; Xunrong Luo; Ali Naji; José Oberholzer; Andrew M Posselt; Camillo Ricordi; Peter A Senior; A M James Shapiro; Peter G Stock; Nicole A Turgeon
Journal:  Am J Transplant       Date:  2020-08-09       Impact factor: 9.369

9.  Stages of change for physical activity and dietary habits in persons with type 2 diabetes included in a mobile health intervention: the Norwegian study in RENEWING HEALTH.

Authors:  Heidi Holmen; Astrid Wahl; Astrid Torbjørnsen; Anne Karen Jenum; Milada Cvancarova Småstuen; Lis Ribu
Journal:  BMJ Open Diabetes Res Care       Date:  2016-05-12

10.  Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.

Authors:  H W Rodbard; B Cariou; B Zinman; Y Handelsman; M L Wolden; A Rana; C Mathieu
Journal:  Diabetes Obes Metab       Date:  2014-02-27       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.